Scancell Holdings (SCLP) H2 2026 earnings summary

Executive summary

• Advanced melanoma Phase 3 trial of iSCIB1+ planned for Q4 2026, following FDA IND clearance and fast track designation and UK MHRA authorization.

• Proposed Neuphoria merger and related financing could fund development plans, but completion depends on shareholder, regulatory and other conditions.

Financial highlights

• FY2026 revenue was £nil vs £4.7m in FY2025; R&D expenses fell to £12.0m from £14.7m, mainly due to lower manufacturing costs.

• Operating loss widened to £17.4m from £15.0m; net loss was £17.9m vs £12.3m, with no £1.8m convertible-note modification gain recorded in FY2026.

• Cash and cash equivalents were £5.3m at 30 April 2026 vs £16.9m a year earlier; net cash used in operating activities was £10.8m.

Outlook and guidance

• Phase 3 iSCIB1+ trial targeting ~550 patients with unresectable Stage IIIB or IV melanoma is expected to start in Q4 2026; further Phase 2 SCOPE PFS data expected in H1 2027.

• A randomized neoadjuvant/adjuvant iSCIB1+ Phase 2 trial is intended for H1 2027, subject to financing and regulatory clearance.

• Further ModiFY data for HNSCC and RCC are expected later in 2026.